COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Gemfibrozil for Nicotine Smoking Cessation (GEMNIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02638597
Recruitment Status : Completed
First Posted : December 23, 2015
Results First Posted : February 1, 2019
Last Update Posted : February 1, 2019
Information provided by (Responsible Party):
Madhukar H. Trivedi, MD, University of Texas Southwestern Medical Center

Brief Summary:
This project will test whether gemfibrozil, a well-studied medication for high cholesterol, will help people stop smoking nicotine cigarette smoking. The study will also test whether gemfibrozil decrease cravings for cigarette and the desire to smoke.

Condition or disease Intervention/treatment Phase
Smoking Cessation Drug: Gemfibrozil Behavioral: smoking cessation counseling Phase 2

Detailed Description:
This is a pilot clinical trial examining the feasibility and efficacy of gemfibrozil treatment for smoking cessation. Adults with a desire to quit nicotine cigarette smoking will be recruited. Eligible participants will be randomly divided into two groups: those who receive gemfibrozil and waitlist controls. Screening will be conducted with a brief phone screen followed by a longer screening visit for those who qualify. During the screening visit, all study participants will provide demographic information and will be interviewed regarding smoking history. Procedures performed during the screening visit include a blood draw, urine pregnancy test, physical exam, clinical psychiatric interview, and measurement of exhaled carbon monoxide (CO). At baseline, participants will complete the Heavy Smoking Index (HSI) and the Brief Questionnaire of Smoking Urges (QSU-Brief). Participants will also complete the Quick Inventory of Depressive Symptoms-Self Rated (QIDS-SR) to assess symptoms of depression and changes in mood associated with smoking cessation will be assessed with the Concise Associated Symptoms Tracking (CAST) scale . Participants will work with the research clinician to set a target quit date within one week of the baseline session, and all participants will be provided written materials with guidance for smoking cessation as part of a smoking cessation counseling session. All participants will attend visits at the research clinic at 3 days and 4 weeks from target quit date to assess safety, adherence, and smoking status; participants will also receive additional smoking cessation counseling. Smoking status will be determined with exhaled breath CO and a single item questionnaire regarding the number of cigarettes smoked since target quit date and symptoms of depression and mood changes will again be measured. Medication side effects will be quantified using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale. The final study visit will occur at 8 weeks after target quit date for completion of the HSI, QIDS-SR, CAST, FIBSER, exhaled breath CO, QSU-Brief, and smoking self-report.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gemfibrozil for Nicotine Smoking Cessation
Study Start Date : February 2015
Actual Primary Completion Date : December 23, 2016
Actual Study Completion Date : December 23, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Gemfibrozil

Arm Intervention/treatment
Experimental: Gemfibrozil
Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
Drug: Gemfibrozil
FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
Other Name: Lopid

Behavioral: smoking cessation counseling
smoking cessation counseling

Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
Behavioral: smoking cessation counseling
smoking cessation counseling

Primary Outcome Measures :
  1. Exhaled Carbon Monoxide (CO) [ Time Frame: 8 weeks after target quit date ]
    Exhaled carbon monoxide change from baseline to last available visit.

Secondary Outcome Measures :
  1. Heaviness of Smoking Index [ Time Frame: 8 weeks after target quit date ]
    The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-64 years
  • Meet DSM-5 criteria for tobacco use disorder based on cigarette use
  • Desire to quit smoking
  • Able to complete assessments and interview in English

Exclusion Criteria:

  • Psychiatric co-morbidity posing safety risk, including current suicidality or psychosis as assessed on clinical interview
  • Concurrent use of a statin medication (HMG-CoA reductase inhibitor),anticoagulant, or repaglinide
  • Concurrent use of any FDA-approved medication for smoking cessation
  • Use of any form of tobacco or nicotine (including vaporizer) other than cigarette smoking
  • Any DSM-5 substance use disorder other than nicotine use disorder
  • History of intolerance to any fibrate medication
  • History of gallbladder disease and cholestectomy has not been performed
  • Baseline liver function tests > twice the upper limit of normal
  • Severe impairment of renal function (baseline serum creatinine ≥ 2 mg/dL)
  • Currently pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02638597

Layout table for location information
United States, Texas
Parkland Memorial Hospital
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Layout table for investigator information
Principal Investigator: Madhukar Trivedi, MD University of Texas Southwestern Medical Center
Layout table for additonal information
Responsible Party: Madhukar H. Trivedi, MD, University of Texas Southwestern Medical Center Identifier: NCT02638597    
Other Study ID Numbers: STU 072014-088
First Posted: December 23, 2015    Key Record Dates
Results First Posted: February 1, 2019
Last Update Posted: February 1, 2019
Last Verified: January 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors